MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Aptose Biosciences Inc. (NASDAQ:APTO)*
Organization & Developments: Aptose Biosciences
Parents
Aptose Biosciences Inc. (NASDAQ:APTO)*
Children
2017: Clinical trials are due to commence in 2018.
2017: FDA GRANTS ORPHAN DRUG DESIGNATION TO APTOSE _Aptose Biosciences
2017: FDA has granted orphan drug designation for CG’806, its pre-clinical candidate for the treatment of patients with acute myeloid leukemia (AML).
2021: Aptose Biosciences: An Assessment
2022: Aptose Biosciences: Expansion Studies Could Rebuild Investor Interest In This Beaten-Down Biotech_ seekingalpha.com
Jumps
Finance & Acquisitions: Aptose Biosciences
Key People: Aptose Biosciences